VERDICT.md — a real audit report

Produced by brief 67 · Venture Verdict, run as a Gut Check dogfood on flaky-test detection & management for CI, synthesizing DEMAND.md and COMPETITORS.md. Sample report. Sources in the underlying reports; access date 2026-07-07.

Reports on hand

DEMAND.md (brief 62) and COMPETITORS.md (brief 63). Missing by design — this is a Gut Check (62·63·67), not the full Founder Funnel: no NICHE, MARKET, POSITIONING, or MOAT report. A verdict can survive the absence for a go/pivot/kill triage, but any "go" here is explicitly provisional on running the full funnel next.

The bars (written before scoring)

Pain reality — needs verbatim, dated evidence of recurring, severe pain from sufferers, not only sellers.
Path to ten customers — the first ten buyers must be nameable as types-with-addresses.
Competitive survivability — a wedge that incumbents can't trivially copy within a release or two.
Economics floor — a plausible price above the free-retry-plugin floor and below Datadog's ceiling.
Why-now — a reason this is a 2026 opportunity, not a 2019 one.
Disconfirmation — the bear case must have gotten real effort in the source reports.

The scorecard

Bar	Evidence	Pass?
Pain reality	Real, per-merge, emotionally-charged; but the loudest, most linkable voices are vendors + Google, not independent dated sufferers (DEMAND silence test)	Partial
Path to ten	Nameable: DevEx/platform ICs at mid-size eng orgs; the "ten people" list is concrete	Pass
Competitive survivability	Detection is commoditizing into free CI features + Datadog; only the root-cause/prevention gap resists copying, and it's unproven	Fail (at the commodity layer); conditional pass only on the hard wedge)
Economics floor	Squeezed: free retry plugins below, platform-bundling above; standalone WTP unclear	Partial/Fail
Why-now	Weak in evidence — no strong 2026-specific catalyst surfaced (AI-assisted root-causing is a candidate but unproven here)	Fail
Disconfirmation	Both reports carried an explicit, equal-weight counter-read	Pass

The ruling

PIVOT — axis: product (and sharpen the customer).

The pain is real and recurring, and the first ten customers are nameable — but the idea as scoped (flaky-test detection & management) fails competitive survivability and economics: detection is commoditizing into free CI features and into Datadog, squeezing standalone pricing between a free floor and a platform ceiling. A single hard fail is not averaged away. The evidence does support a narrower bet: pivot from "detect & quarantine" to "root-cause once & prevent" — the one gap COMPETITORS.md found open because it is hard, not because it is worthless, and the direct answer to the buyer's unmet "and then what?" This is the operator's hope (a defensible wedge exists) reconciled with what the evidence says (the commodity layer is lost) — both labeled, per the rules.

If pivot — the first three actions and tripwires

Prove the hard wedge is buildable: prototype root-cause attribution on a real flaky suite; if it can't beat "quarantine + rerun" in a blind test, kill.
Interview the ten: validate that teams will pay more for prevention than they pay (nothing) for detection today.
Run the full Founder Funnel (NICHE → MARKET → POSITIONING → MOAT) on the pivoted product before any build commitment — this Gut Check deliberately skipped them.
Tripwires: GitHub/CircleCI ship free root-causing (moat gone); interviews reveal detection is "good enough" (WTP ceiling confirmed); prototype accuracy stalls below quarantine's usefulness.

What this teaches the next candidate

When a category's leaders lead with emotion rather than outcome, read it twice: it can mean the pain is vivid or that the category is crowded and shouting. Here it was both — the tie-breaker was the economics squeeze, not the pain. Bars set before scoring are what let a real, painful, well-funded-looking market still return a pivot instead of an enthusiastic go.

Report only — accept the ruling, or challenge a bar (e.g. is the why-now bar too strict for a tooling play)?